Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Japan colorectal tumor prevention study: randomized controlled trial by low-dose aspirin

ABSTRACT: Interventions: Aspirin (100 mg/day) enteric-coated tablet Placebo tablet / day Primary outcome(s): Only the occurrence of a colorectal tumor (adenoma or cancer) is selected as the primary endpoint. Study Design: Parallel Randomized

DISEASE(S): Colorectal Tumor

PROVIDER: 2616201 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Japan colorectal tumor prevention study: clinical trial by low-dose aspirin

Project description:Interventions: aspirin enteric-coated tablet (100 mg, one tablet daily) for four years Primary outcome(s): The primary endpoint is set as the incidence of newly diagnosed colorectal Index Lesion (adenomas >= 10 mm in diameter, adenomas with high-grade dysplasia, or invasive cancer) during 4 years observation excluding the first year observation. Study Design: Single arm Non-randomized

| 2634032 | ecrin-mdr-crc

Novel single nucleotide polymorphism markers for low dose aspirin-associated small bowel bleeding

Project description:Blood from 17 patients taking enteric-coated low-dose aspirin (LDA) and with suspected bleeding from small intestine and 18 control patients taking aspirin were analyzed. Results provide insight into the risk for aspirin-induced small bowel bleeding.

2013-11-08 | GSE52155 | GEO

Novel single nucleotide polymorphism markers for low dose aspirin-associated small bowel bleeding

2013-11-08 | E-GEOD-52155 | biostudies-arrayexpress

Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers

Project description:A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention Programme (CaPP3).

| 2194130 | ecrin-mdr-crc

Placental Effects of Aspirin treatment in preeclamptic women

Project description:Aspirin is currently the only drug used in preeclampsia, a major hypertensive disorder of pregnancy. The counselled doses are low (75-150 mg/day), and the actual effects of aspirin are not well understood, especially in the target organ, the placenta.This is the aim of the present study.

2022-12-31 | E-MTAB-12434 | biostudies-arrayexpress

Aspirin Challenge–Induced Genome-Wide DNA Methylation Profile of Peripheral Blood Lymphocytes in Aspirin-Exacerbated Respiratory Disease

Project description:Oral aspirin challenge may induce different global CpG methylation patterns between aspirin-exacerbated respiratory disease (AERD) and aspirin-tolerant asthma (ATA), which may affect gene expression several hours later. Therefore, in the present study, we compared global CpG methylation profiles before and after an oral aspirin challenge in patients with asthma. In addition, we compared differences in methylation profiles between AERD and ATA using an Illumina 860K Infinium Methylation EPIC BeadChip array platform, which had greater coverage than in the previous study (26,485 CpGs) to discover new methylated CpGs in PBLs associated with aspirin-induced bronchospasm.

2023-06-27 | GSE235569 | GEO

Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin

Project description:The study protocol for both cohorts has been previously described (Journal of Thrombosis and Thrombolysis 2012:1-12). HV1 cohort: Briefly 50 healthy volunteers were exposed to two weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by microarray before and after aspirin exposure. The pre-aspirin samples were profiled on the U133A 2.0 array and the post-aspirin samples were profiled on the U1333plus 2.0 array. HV2 cohort: Briefly 53 healthy volunteers were exposed to four weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by U133plus 2.0 array before and after aspirin exposure.

| phs000548.v1.p1 | EGA

Half-lives of aspirin-mediated lysine acetylations

Project description:Aspirin, or acetylsalicylic acid is widely used to control pain, inflammation and fever. An important property of aspirin is its ability to acetylate multiple cellular proteins with some pharmacological functions explicable by the irreversible acetylation of cyclooxygenases at active site serine residues. We have used a labeled form of aspirin, aspirin-d3 to acetylate proteins in cultured human cells, and unambiguously identified over 12000 sites of acetylation, using acetylated lysine peptide enrichment combined with mass-spectrometry-based proteomics. Aspirin increases lysine acetylation occupancy of the majority of detected endogenous sites, but leaves almost unchanged a small group that are already highly acetylated. We show that cells are remarkably tolerant of this acetylation insult unless endogenous deacetylases are inhibited. This work raises the possibility that rather than single protein effects, some of the clinical features of aspirin may be the consequence of multiple concurrent protein modifications, and that combining aspirin with lysine deacetylase inhibitors may have important medical implications.

2019-03-05 | PXD003655 | Pride

Sites of aspirin-mediated lysine acetylation in HeLa cells

Project description:Aspirin, or acetylsalicylic acid is widely used to control pain, inflammation and fever. Important to this function is its ability to irreversibly acetylate cyclooxygenases at active site serines. Aspirin has the potential to acetylate other amino-acid side-chains, leading to speculation that aspirin-mediated lysine acetylation could explain some of its drug actions or side-effects. Using a labeled form of aspirin, aspirin-d3, we identified over 12000 sites of lysine acetylation from cultured human cells. Although aspirin amplifies acetylation signals at thousands of sites, cells tolerate aspirin mediated acetylation very well unless endogenous deacetylases are inhibited. Apart from a limited number of cellular proteins that are substantially acetylated under endogenous conditions, aspirin mediated acetylation leads to a large increase in the acetylation of many proteins even although they remain at very low stoichiometry. This reinforces the idea that a major function of cellular deacetylases is the suppression of non-specific or non-enzymatic protein acetylation.

2017-01-10 | PXD003530 | Pride

Aspirin Pharmacogenomics

| phs000548 | dbGaP